Key result
Atorvastatin daily triggers severe rhabdomyolysis mimicking Guillain-Barré syndrome, reversible with prompt drug cessation.
Case Report (n=1)
Answers are grounded in this paper and cite their sources.
Severe statin-associated rhabdomyolysis can present with mixed electrophysiological features mimicking Guillain-Barré syndrome, emphasizing the need for early recognition and statin withdrawal.
Statin-associated myopathy represents a well-recognised adverse effect of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors, ranging from myalgia to life-threatening rhabdomyolysis. Neurological involvement in the form of peripheral neuropathy mimicking Guillain-Barré syndrome (GBS) is rare and diagnostically challenging. We report a case of a 72-year-old man with diabetes mellitus, hypertension, and single-vessel coronary artery disease who underwent percutaneous transluminal coronary angioplasty (PTCA) and was initiated on atorvastatin 40 mg once daily as secondary prevention. Within two months of initiation, he developed myoglobinuria followed by rapidly evolving bilateral upper and lower limb weakness on admission. Peak creatine kinase (CK) was 48,000 U/L, with urine myoglobin exceeding 12,000 ng/mL. Nerve conduction studies demonstrated a lower-motor-neuron-type demyelinating sensorimotor polyneuropathy, while electromyography revealed a myopathic pattern. Although GBS was a primary diagnostic concern, cerebrospinal fluid analysis did not corroborate due to the absence of albuminocytologic dissociation. The patient was managed with statin discontinuation and aggressive intravenous fluid resuscitation. Myoglobinuria started to resolve by day two. At discharge, upper limb weakness had fully resolved, and lower limb power improved from 1/5 to 3/5, with CK declining to 8060 U/L. This case highlights that severe statin-associated rhabdomyolysis with mixed electrophysiological features of demyelinating polyneuropathy and myopathy can closely mimic GBS. The significant clinical improvement following statin withdrawal without immunomodulatory therapy favours a toxic neuromyopathic process over an immune-mediated aetiology, emphasising early recognition and prompt discontinuation of the offending agent to prevent complications and improve outcomes.
No takes yet. Share an insight, caveat, or question.
Chatterjee et al. (2026) conducted a case report in Statin-associated severe rhabdomyolysis mimicking Guillain-Barré syndrome (n=1). Atorvastatin was evaluated. Atorvastatin daily induced severe rhabdomyolysis mimicking Guillain-Barré syndrome, which improved following statin withdrawal and fluid resuscitation.
Synapse has enriched 10 related papers. Consider them for comparative context: